| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
Etosalamide targets the cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2, which are responsible for the production of prostaglandins from arachidonic acid. By inhibiting COX activity, it reduces the synthesis of prostaglandins, which are key mediators of inflammation, pain, and fever. Its salicylamide structure is related to other NSAIDs like salicylamide and aspirin, but its precise selectivity and potency for COX isoforms are less characterized.
|
|---|---|
| ln Vitro |
In vitro, Etosalamide has been shown to inhibit prostaglandin synthesis in various cell-based and enzyme-based assays. It demonstrates anti-inflammatory activity by reducing the production of pro-inflammatory mediators. In Phase II metabolic studies, etofesalamide (a related compound) has been shown to be metabolized by filamentous fungi into glucoside and riboside conjugates.
|
| ln Vivo |
In vivo, Etosalamide has antipyretic and analgesic effects, consistent with its classification as an NSAID. It has been used to treat pain and inflammation in various settings. Its anti-inflammatory activity suggests potential for use in allergic disease models. However, specific in vivo efficacy data in animal models are limited in the available literature.
|
| Enzyme Assay |
In vitro enzyme assays for Etosalamide typically measure the inhibition of cyclooxygenase (COX-1 and COX-2) activity. The enzyme is incubated with arachidonic acid and varying concentrations of Etosalamide, and the production of prostaglandin E2 (PGE2) or other prostaglandins is measured by ELISA or radioimmunoassay. IC₅₀ values are calculated from dose-response curves to determine potency and selectivity.
|
| Cell Assay |
In vitro cell-based assays for Etosalamide are performed using cell lines such as macrophages or fibroblasts that produce prostaglandins in response to inflammatory stimuli. Cells are cultured in appropriate media and treated with Etosalamide at various concentrations prior to stimulation with lipopolysaccharide (LPS) or other inflammatory agents. Prostaglandin levels in the culture medium are measured by ELISA, and cell viability is assessed by MTT assays.
|
| Animal Protocol |
In vivo animal studies for Etosalamide would typically involve rodent models of inflammation and pain, such as the carrageenan-induced paw edema model for inflammation or the acetic acid-induced writhing test for analgesia. The compound is administered orally or intraperitoneally, and the reduction in edema or pain response is measured. However, specific protocols are not extensively detailed in the available literature.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic properties of Etosalamide, such as half-life and oral bioavailability, are not extensively characterized. As a salicylamide derivative, it is expected to be absorbed from the gastrointestinal tract, metabolized in the liver (likely through conjugation and hydroxylation), and excreted primarily in urine. Its pharmacokinetic profile may be similar to other salicylamide-based NSAIDs.
|
| Toxicity/Toxicokinetics |
Etosalamide is generally well-tolerated, but like other NSAIDs, it may cause gastrointestinal side effects such as nausea, dyspepsia, and gastric irritation. At high doses, it may cause renal and hepatic effects. It is contraindicated in patients with known hypersensitivity to salicylates or NSAIDs. As a research compound, it is intended for laboratory use only and is not for human therapeutic use.
|
| References |
Acta Pharmacol Sin.2005 Jul;26(7):893-6.
|
| Additional Infomation |
Etosalamide is a salicylamide derivative and NSAID with antipyretic, analgesic, and anti-inflammatory activity. It is also known as Ethosalamide and o-(2-Ethoxyethoxy)benzamide. The compound has potential applications in allergic disease research. It is supplied with a purity of ≥98% and is for research use only.
|
| Molecular Formula |
C11H15NO3
|
|---|---|
| Molecular Weight |
209.241703271866
|
| Exact Mass |
209.105
|
| CAS # |
15302-15-5
|
| PubChem CID |
208946
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
1.901
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
15
|
| Complexity |
196
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C1=CC=CC=C1C(N([H])[H])=O)CCOCC
|
| InChi Key |
XBNRCMFFZFCWMH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H15NO3/c1-2-14-7-8-15-10-6-4-3-5-9(10)11(12)13/h3-6H,2,7-8H2,1H3,(H2,12,13)
|
| Chemical Name |
o-(2-Ethoxyethoxy)benzamide
|
| Synonyms |
Ethosalamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~300 mg/mL (~1433.76 mM)
H2O : ~6.67 mg/mL (~31.88 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (11.95 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (11.95 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (11.95 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.7792 mL | 23.8960 mL | 47.7920 mL | |
| 5 mM | 0.9558 mL | 4.7792 mL | 9.5584 mL | |
| 10 mM | 0.4779 mL | 2.3896 mL | 4.7792 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA